|
1 2 3 4 5 6 7
читать далее ... 6. Thorpe SC. Azmatullah S. Fellows GJ et al. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment ofmetastatic prostatic carcinoma Eur Urol 1996: 29(1): 47-54. 7. Moffat LE. Comparison of Zoladex. diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol. 1990: 18 SuppI 3: 26-7. 8. Goldenberg SL, Bruchovsky /V Use of cyproterone acetate in prostate cancer. Urol Clin North Am. 1991 Feb:18(1):111-22. 9. Ostri P, Bonnesen T. Nilsson T, Frimodt-Moller C. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial. 10. Pavone-Macaluso M, de VoogtHJ, Viggiano G etal. Comparison of diethylstilbestrol. cyproterone acetate and medroxyprogesferone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization tor Research on Treatment of Cancer Urological Group. J Urol. 1986 Sep:136<3):624-31. 11. Schroder FH. Collette L, de Reijke TM. Whelan P. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer. 2000 Jan:82(2):283-90. 12. Lund F. Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. Br J Urol. 1988 Feb:61(2):140-2. 13. Delaere KP, Van Thillo EL Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol. 1991 Oct:18(5 SuppI 6):13-8. 14. Boccon-Gibod L. Fournier G, Bottet P et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol. 1997:32(4):391-5: discussion 395-6. 15. ChangA. Yeap 8, Davis Tetal. Double-blind, randomized study of primary hormonal treatment of stage 02 prostate carcinoma: flutamide versus diethylstilbestrol J Clin Oncol. 1996Aug:14(8):2250-7. 16. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FMLong-ferm efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol. 1997Jul:158(1 ):160-3. 17. Chodak GW, Sharifi R. Rfsimis В et al. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46 (б): рр: 849-855. 18. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cfnctr. Urology 1996: 47 (1A) SuppI. Pp. 38-43. 19. Kolvenbag GJ. l\lash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate 39: 47, 1999. 20. Boccardo F., Rubagotti A., Banchello M. etal. Bicalutamide monotherapy versus flufamide plus gosereline in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol? 17:2027, 1999.Источник: Русаков И.Г., Алексеев Б.Я. Русский медицинский журнал. 2005. Т.13. №15. С.1042-1045
|
